1. Home
  2. AARD vs ATLN Comparison

AARD vs ATLN Comparison

Compare AARD & ATLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AARD
  • ATLN
  • Stock Information
  • Founded
  • AARD 2017
  • ATLN 2014
  • Country
  • AARD United States
  • ATLN United States
  • Employees
  • AARD N/A
  • ATLN N/A
  • Industry
  • AARD Biotechnology: Pharmaceutical Preparations
  • ATLN
  • Sector
  • AARD Health Care
  • ATLN
  • Exchange
  • AARD Nasdaq
  • ATLN NYSE
  • Market Cap
  • AARD 154.9M
  • ATLN 140.1M
  • IPO Year
  • AARD 2025
  • ATLN 2021
  • Fundamental
  • Price
  • AARD $13.68
  • ATLN $1.77
  • Analyst Decision
  • AARD Strong Buy
  • ATLN
  • Analyst Count
  • AARD 5
  • ATLN 0
  • Target Price
  • AARD $33.00
  • ATLN N/A
  • AVG Volume (30 Days)
  • AARD 84.2K
  • ATLN 70.6K
  • Earning Date
  • AARD 08-14-2025
  • ATLN 08-22-2025
  • Dividend Yield
  • AARD N/A
  • ATLN N/A
  • EPS Growth
  • AARD N/A
  • ATLN N/A
  • EPS
  • AARD N/A
  • ATLN N/A
  • Revenue
  • AARD N/A
  • ATLN $444,795,409.00
  • Revenue This Year
  • AARD N/A
  • ATLN N/A
  • Revenue Next Year
  • AARD N/A
  • ATLN N/A
  • P/E Ratio
  • AARD N/A
  • ATLN N/A
  • Revenue Growth
  • AARD N/A
  • ATLN 10.11
  • 52 Week Low
  • AARD $4.88
  • ATLN $1.68
  • 52 Week High
  • AARD $19.58
  • ATLN $7.97
  • Technical
  • Relative Strength Index (RSI)
  • AARD N/A
  • ATLN N/A
  • Support Level
  • AARD N/A
  • ATLN N/A
  • Resistance Level
  • AARD N/A
  • ATLN N/A
  • Average True Range (ATR)
  • AARD 0.00
  • ATLN 0.00
  • MACD
  • AARD 0.00
  • ATLN 0.00
  • Stochastic Oscillator
  • AARD 0.00
  • ATLN 0.00

About AARD Aardvark Therapeutics Inc. Common Stock

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

About ATLN ATLANTIC INTERNATIONAL CORP

Atlantic International Corp is a U.S.-based outsourced services and workforce solutions company. The company specializes in permanent, temporary, and temporary-to-permanent placement services in various areas, including accounting and finance, administrative and clerical, hospitality, information technology, legal, light industrial, and medical fields. It also provides productivity consulting and workforce management solutions.

Share on Social Networks: